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Background
Cellular CD4 induces HIV-1 gp120 into a unique confor-
mation (CD4i) which is thought to expose previously
concealed neutralizing gp120 epitopes. Therefore, CD4/
gp120 complex has been considered as a potential HIV
candidate vaccine. However, this complex is not without
drawbacks. As part of an immuno-complex, CD4 might
be expected to elicit an autoimmune response. Moreover,
the CD4-induced conformation of gp120 is the result of
occlusion of the CD4 binding site itself thus forfeiting a
major neutralizing epitope of the envelope. In view of
this, we sought to isolate gp120 binding peptides that sta-
bilize gp120 in the CD4i conformation without occluding
the CD4 binding site. Such peptides would function as
immuno-modulators of gp120 conformation and could
be useful in vaccine design. Therefore, through screening
of a combinatorial phage display library comprised of
random 12-mer cys-looped peptides, we succeeded in iso-
lating a gp120451 specific peptide, designated m-1. The
m-1 peptide locked gp120 into the CD4i conformation, as
illustrated by the binding of the CD4i-mAb CG10. More-
over, m-1 was found not to occlude the CD4 binding site,
as it continued to bind gp120 in the presence of soluble
CD4. The m-1/gp120 complex was also found to main-
tain the integrity of other highly neutralizing epitopes
such as that of the b12 mAb in addition to the CD4i
epitopes. As such, the complex is regarded as a viable
immunogen for vaccine development.
Objective
To develop a second generation peptide immuno-modu-
lator based on the lead peptide m-1 with improved affin-
ity for gp120 and expanded cross-reactivity for other HIV
gp120 variants. For this we have combined the power of
genetic engineering with the strength of combinatorial
technology.
Results
In order to modify the m-1 peptide, a novel phage display
library was constructed based on the m-1 gene using oli-
gonucleotides which have undergone biased random
mutagenesis. Briefly, this approach is based on the synthe-
sis of corresponding oligonucleotides using phosphora-
midite monomer precursors contaminated with regulated
amounts of the other three possible phosphoramidites
thus, generating a limited number of mutations in the
synthesized sequence. Our «biased» library contained 4 ×
108 mutant phage-displayed peptides, differing from the
m-1 sequence by 3–4 amino acids/peptide and was subse-
quently screened against gp120451. A number of affinity
purified phages were isolated that bound gp120 better
than the original m-1 and were also improved CG10
inducers. To further select for improved gp120 binders,
bio-panning was performed at high stringency conditions.
In the process of doing so, a novel derivative of m-1 was
selected. This phage-displayed peptide, designated m-2,
had 10-fold improved binding to gp120. Moreover, m-2
was able to bind gp120s from various HIV strains
(gp120BaL, gp120JRFL) in addition to gp120451.
Conclusion
Using genetic engineering and functional screening we
have obtained the m-2 peptide, which effectively locks
gp120 into a CD4i conformation, maintains the integrity
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of the b12 epitope and retains a free CD4 binding site. In
light of this, m-2 represents a new class of immuno-mod-
ulators for future AIDS vaccine design.